AbCellera Biologics Inc. Shareholders' Equity
AbCellera Biologics Inc. (ABCL) had Shareholders' Equity of $896.02 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $896.02M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $938.08M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $966.90M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $964.04M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $896.02M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $938.08M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $966.90M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $964.04M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.01B 10-Q · filed 2026-08-05 |
| 2025-03-31 | $1.02B 10-Q · filed 2026-08-05 |
| 2024-12-31 | $1.06B 10-Q · filed 2026-08-05 |
| 2024-09-30 | $1.08B 10-Q · filed 2025-11-06 |
| 2024-06-30 | $1.11B 10-Q · filed 2025-11-06 |
| 2024-03-31 | $1.13B 10-Q · filed 2025-11-06 |
| 2023-12-31 | $1.15B 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.18B 10-Q · filed 2024-11-04 |
| 2023-06-30 | $1.19B 10-Q · filed 2024-11-04 |
| 2023-03-31 | $1.21B 10-Q · filed 2024-11-04 |
| 2022-12-31 | $1.23B 10-K · filed 2026-02-24 |
| 2022-09-30 | $1.25B 10-Q · filed 2023-11-02 |
| 2022-06-30 | $1.21B 10-Q · filed 2023-11-02 |
| 2022-03-31 | $1.21B 10-Q · filed 2023-11-02 |
| 2021-12-31 | $1.03B 10-K · filed 2025-02-27 |
| 2021-09-30 | $953.40M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $967.68M 10-Q · filed 2022-11-08 |
| 2021-03-31 | $957.12M 10-Q · filed 2022-11-08 |
| 2020-12-31 | $830.51M 10-K · filed 2024-02-20 |
| 2020-09-30 | $89.26M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $90.89M 10-Q · filed 2021-11-10 |
| 2020-03-31 | $83.69M 10-Q · filed 2021-11-10 |
| 2019-12-31 | $10.25M 10-K · filed 2023-02-21 |
| 2018-12-31 | $11.61M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |